SECIRA-UM (oogmelanoom)


Protocolnummer:
NTR3488

Ziekenhuizen:
NKI / A.v.L ziekenhuis Amsterdam

Titel:
Phase 1b/ll study exploring safety and efficacy of the combination or ipilimumab with radiofrequency ablation (RFA) in patients with unresectable uveal melanoma liver metastases.

Behandeling:
RFA + ipilimumab

Stadium:
Oogmelanoom

Belangrijkste in/exclusiecriteria:
In: Confirmed unresectable metastatic uveal melanoma, at least two liver metastases with at least one feasible for RFA, no prior systemic treatment, local pretreatment is allowed, no concurrent immunosuppressive medications. Ex: Cerebral or meningeal metastasized uveal melanoma, infection with HIV, any active autoimmune disease that require immunosuppressive medications except for vitiligo or resolved childhood asthma

Contactpersoon:
Dr. C. Blank (NKI-AVL)

Alle melanoom trials